Integrating gepants into clinical practice for the acute treatment of migraine - PubMed
3 days ago
- #migraine
- #triptans
- #gepants
- Gepants are small-molecule calcitonin gene-related peptide receptor antagonists used for acute migraine treatment.
- Triptans are widely prescribed for migraine but have cardiovascular contraindications and may cause inadequate symptom relief or poor tolerability.
- Gepants offer advantages such as favorable tolerability, efficacy in both prodromal and headache phases, and no cardiovascular contraindications.
- Gepants are suitable for patients with triptan contraindications, inadequate response, or intolerance.
- Clinical trials support gepants' efficacy and safety, including in triptan insufficient responders.
- Gepants are unlikely to cause medication-overuse headache, unlike triptans.
- Ubrogepant has shown efficacy in preventing headache onset during the prodrome, a benefit not seen with triptans.
- Disadvantages of gepants include cost, access limitations, and CYP3A4 drug interactions.
- Head-to-head studies are needed to compare the effectiveness of gepants and triptans directly.